111 related articles for article (PubMed ID: 31702065)
1. Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma.
Wudhikarn K; Bunworasate U; Julamanee J; Lekhakula A; Ekwattanakit S; Khuhapinant A; Niparuck P; Chuncharunee S; Numbenjapon T; Prayongratana K; Kanitsap N; Wongkhantee S; Makruasri N; Wong P; Norasetthada L; Nawarawong W; Sirijerachai C; Chansung K; Suwanban T; Praditsuktavorn P; Intragumtornchai T;
Hematol Oncol; 2019 Dec; 37(5):578-585. PubMed ID: 31702065
[TBL] [Abstract][Full Text] [Related]
2. Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study.
Kim YR; Kim SJ; Lee HS; Jeon S; Cho H; Chung H; Jang JE; Cheong JW; Min YH; Kim JS
Cancer Res Treat; 2022 Apr; 54(2):613-620. PubMed ID: 34352996
[TBL] [Abstract][Full Text] [Related]
3. International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.
Maurer MJ; Ellin F; Srour L; Jerkeman M; Bennani NN; Connors JM; Slack GW; Smedby KE; Ansell SM; Link BK; Cerhan JR; Relander T; Savage KJ; Feldman AL
J Clin Oncol; 2017 Dec; 35(36):4019-4026. PubMed ID: 29072976
[TBL] [Abstract][Full Text] [Related]
4. Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma.
Chen H; Qin Y; Yang J; Liu P; Zhang C; He X; Zhou S; Yang S; Gui L; Zhou L; Sun Y; Shi Y
Ann Hematol; 2020 Dec; 99(12):2847-2857. PubMed ID: 32712792
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS.
Cao Z; Wang X; Xue X; Feng X
Ann Hematol; 2024 Mar; 103(3):869-883. PubMed ID: 38040859
[TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
[TBL] [Abstract][Full Text] [Related]
7. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
[TBL] [Abstract][Full Text] [Related]
8. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation.
Prochazka V; Faber E; Raida L; Papajik T; Vondrakova J; Rusinakova Z; Kucerova L; Myslivecek M; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Mar; 155(1):63-9. PubMed ID: 21475380
[TBL] [Abstract][Full Text] [Related]
10. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
[TBL] [Abstract][Full Text] [Related]
11. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
Prochazka V; Faber E; Raida L; Vondrakova J; Kucerova L; Jarosova M; Indrak K; Papajik T
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):63-6. PubMed ID: 19365529
[TBL] [Abstract][Full Text] [Related]
12. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
Han X; Zhang W; Zhou D; Ruan J; Duan M; Zhu T; Li J; Cai H; Cao X; Ouyang M
J Int Med Res; 2017 Feb; 45(1):290-302. PubMed ID: 28222648
[TBL] [Abstract][Full Text] [Related]
13. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.
Maurer MJ; Jais JP; Ghesquières H; Witzig TE; Hong F; Haioun C; Thompson CA; Thieblemont C; Micallef IN; Porrata LF; Ribrag V; Nowakowski GS; Casasnovas O; Bologna S; Morschhauser F; Morrison VA; Peterson BA; Macon WR; Copie-Bergman C; Feldman AL; Syrbu SI; Kurtin PJ; Gascoyne RD; Li H; Allmer C; Kahl BS; Ansell SM; Slager SL; Link BK; Salles G; Habermann TM; Tilly H; Cerhan JR
Am J Hematol; 2016 Feb; 91(2):179-84. PubMed ID: 26492520
[TBL] [Abstract][Full Text] [Related]
14. Event-free survival at 12 months is a strong surrogate endpoint for stage 1 diffuse large B cell lymphoma: a report from Nation Wide Registry Thai Lymphoma Study Group.
Wudhikarn K; Bunworasate U; Julamanee J; Lekhakula A; Ekwattanakit S; Khuhapinant A; Niparuck P; Chuncharunee S; Numbenjapon T; Prayongratana K; Kanitsap N; Wongkhantee S; Makruasi N; Wong P; Norasetthada L; Nawarawong W; Sirijerachai C; Chansung K; Suwanban T; Praditsuktavorn P; Intragumtornchai T
Leuk Lymphoma; 2020 Nov; 61(11):2614-2621. PubMed ID: 32573294
[TBL] [Abstract][Full Text] [Related]
15. Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL).
Zhang JY; Briski R; Devata S; Kaminski MS; Phillips TJ; Mayer TL; Bailey NG; Wilcox RA
Am J Hematol; 2018 Mar; 93(3):394-400. PubMed ID: 29194714
[TBL] [Abstract][Full Text] [Related]
16. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience.
Rohlfing S; Dietrich S; Witzens-Harig M; Hegenbart U; Schönland S; Luft T; Ho AD; Dreger P
Ann Hematol; 2018 Jul; 97(7):1241-1250. PubMed ID: 29549411
[TBL] [Abstract][Full Text] [Related]
17. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.
Blystad AK; Enblad G; Kvaløy S; Berglund A; Delabie J; Holte H; Carlson K; Kvalheim G; Bengtsson M; Hagberg H
Bone Marrow Transplant; 2001 Apr; 27(7):711-6. PubMed ID: 11360110
[TBL] [Abstract][Full Text] [Related]
18. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
[TBL] [Abstract][Full Text] [Related]
19. Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database.
Bhatt VR; Giri S; Verma V; Manandhar S; Pathak R; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):373-8. PubMed ID: 27349764
[TBL] [Abstract][Full Text] [Related]
20. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
Chihara D; Fanale MA; Miranda RN; Noorani M; Westin JR; Nastoupil LJ; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Lee HJ; Neelapu SS; Rodriguez MA; Wang M; Fowler NH; Davis RE; Medeiros LJ; Hosing C; Nieto YL; Oki Y
Br J Haematol; 2017 Mar; 176(5):750-758. PubMed ID: 27983760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
